Kreymann B, Williams G, Ghatei MA, Bloom SR: Glucagon-like peptide-1 7–36: a physiological incretin in man. Lancet. 1987, 2: 1300-1304. 10.1016/S0140-6736(87)91194-9.
Article
CAS
PubMed
Google Scholar
Mayo KE, Miller LJ, Bataille D, Dalle S, Goke B, Thorens B, Drucker DJ: International union of pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev. 2003, 55: 167-194. 10.1124/pr.55.1.6.
Article
CAS
PubMed
Google Scholar
Vella A, Shah P, Basu R, Basu A, Holst JJ, Rizza RA: Effect of glucagon-like peptide 1(7–36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. Diabetes. 2000, 49: 611-617. 10.2337/diabetes.49.4.611.
Article
CAS
PubMed
Google Scholar
Egan JM, Bulotta A, Hui H, Perfetti R: GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells. Diabetes Metab Res Rev. 2003, 19: 115-123. 10.1002/dmrr.357.
Article
CAS
PubMed
Google Scholar
Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ: Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci. 1993, 38: 665-673. 10.1007/BF01316798.
Article
CAS
PubMed
Google Scholar
Tolessa T, Gutniak M, Holst JJ, Efendic S, Hellstrom PM: Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin. J Clin Invest. 1998, 102: 764-774. 10.1172/JCI942.
Article
PubMed Central
CAS
PubMed
Google Scholar
Gutzwiller JP, Degen L, Heuss L, Beglinger C: Glucagon-like peptide 1 (GLP-1) and eating. Physiol Behav. 2004, 82: 17-19. 10.1016/j.physbeh.2004.04.019.
Article
CAS
PubMed
Google Scholar
Gutzwiller JP, Degen L, Matzinger D, Prestin S, Beglinger C: Interaction between GLP-1 and CCK-33 in inhibiting food intake and appetite in men. Am J Physiol Regul Integr Comp Physiol. 2004, 287: R562-R567. 10.1152/ajpregu.00599.2003.
Article
CAS
PubMed
Google Scholar
Barnett AH: Exenatide. Drugs Today (Barc). 2005, 41: 563-578. 10.1358/dot.2005.41.9.893704.
Article
CAS
Google Scholar
Iltz JL, Baker DE, Setter SM, Keith Campbell R: Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus. Clin Ther. 2006, 28: 652-665. 10.1016/j.clinthera.2006.05.006.
Article
CAS
PubMed
Google Scholar
Perry T, Greig NH: The glucagon-like peptides: a double-edged therapeutic sword?. Trends Pharmacol Sci. 2003, 24: 377-383. 10.1016/S0165-6147(03)00160-3.
Article
CAS
PubMed
Google Scholar
Madsbad S, Kielgast U, Asmar M, Deacon CF, Torekov SS, Holst JJ: An overview of once-weekly glucagon-like peptide-1 receptor agonists–available efficacy and safety data and perspectives for the future. Diabetes Obes Metab. 2011, 13: 394-407. 10.1111/j.1463-1326.2011.01357.x.
Article
CAS
PubMed
Google Scholar
Holmes AM, Rudd JA, Tattersall FD, Aziz Q, Andrews PL: Opportunities for the replacement of animals in the study of nausea and vomiting. Br J Pharmacol. 2009, 157: 865-880. 10.1111/j.1476-5381.2009.00176.x.
Article
PubMed Central
CAS
PubMed
Google Scholar
Sanger GJ, Holbrook JD, Andrews PL: The translational value of rodent gastrointestinal functions: a cautionary tale. Trends Pharmacol Sci. 2011, 32: 402-409. 10.1016/j.tips.2011.03.009.
Article
CAS
PubMed
Google Scholar
Horn CC, Kimball BA, Wang H, Kaus J, Dienel S, Nagy A, Gathright GR, Yates BJ, Andrews PL: Why can’t rodents vomit? A comparative behavioral, anatomical, and physiological study.PLoS One 2013, 8:e60537.,
Tolessa T, Gutniak M, Holst JJ, Efendic S, Hellstrom PM: Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms. Dig Dis Sci. 1998, 43: 2284-2290. 10.1023/A:1026678925120.
Article
CAS
PubMed
Google Scholar
Combettes MM: GLP-1 and type 2 diabetes: physiology and new clinical advances. Curr Opin Pharmacol. 2006, 6: 598-605. 10.1016/j.coph.2006.08.003.
Article
CAS
PubMed
Google Scholar
Chan SW, He J, Lin G, Rudd JA, Yamamoto K: Action of GLP-1 (7–36) amide and exendin-4 on Suncus murinus (house musk shrew) isolated ileum. Eur J Pharmacol. 2007, 566: 185-191. 10.1016/j.ejphar.2007.03.050.
Article
CAS
PubMed
Google Scholar
Chan SW, Lin G, Yew DT, Rudd JA: A physiological role of glucagon-like peptide-1 receptors in the central nervous system of Suncus murinus (house musk shrew). Eur J Pharmacol. 2011, 668: 340-346. 10.1016/j.ejphar.2011.06.036.
Article
CAS
PubMed
Google Scholar
Chan SW, Lin G, Yew DT, Yeung CK, Rudd JA: Separation of emetic and anorexic responses of exendin-4, a GLP-1 receptor agonist in Suncus murinus (house musk shrew). Neuropharmacology. 2013, 70: 141-147. 10.1016/j.neuropharm.2013.01.013.
Article
CAS
PubMed
Google Scholar
Percie Du Sert N, Holmes AM, Wallis R, Andrews PL: Predicting the emetic liability of novel chemical entities: a comparative study. Br J Pharmacol. 2012, 165: 1848-1867. 10.1111/j.1476-5381.2011.01669.x.
Article
CAS
PubMed
Google Scholar
Percie du Sert N, Andrews PLR: The ferret in nausea and vomiting research: lessons in translation of basic science to the clinic. Biology and Diseases of the Ferret. 2014, John Wiley & Sons, Inc, New Jersey, 735-778. 10.1002/9781118782699.ch31.
Chapter
Google Scholar
Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Goke B: Exendin-4 is a high potency agonist and truncated exendin-(9–39)-amide an antagonist at the glucagon-like peptide 1-(7–36)-amide receptor of insulin-secreting beta-cells. J Biol Chem. 1993, 268: 19650-19655.
CAS
PubMed
Google Scholar
Stern RM, Koch KL, Andrews PLR: Nausea: Mechanisms and Management. 2011, Oxford University Press, Oxford
Google Scholar
Percie Du Sert N, Chu KM, Wai MK, Rudd JA, Andrews PL: Reduced normogastric electrical activity associated with emesis: a telemetric study in ferrets. World J Gastroenterol. 2009, 15: 6034-6043. 10.3748/wjg.15.6034.
Article
PubMed Central
CAS
PubMed
Google Scholar
Kim J, Napadow V, Kuo B, Barbieri R: A combined HRV-fMRI approach to assess cortical control of cardiovagal modulation by motion sickness. Conf Proc IEEE Eng Med Biol Soc. 2011, 2011: 2825-2828.
PubMed Central
CAS
PubMed
Google Scholar
Farmer AD, Al Omran Y, Aziz Q, Andrews PL: The role of the parasympathetic nervous system in visually induced motion sickness: systematic review and meta-analysis. Exp Brain Res. 2014, 232: 2665-2673. 10.1007/s00221-014-3964-3.
Article
CAS
PubMed
Google Scholar
Lawes INC, Andrews PLR: Neuroanatomy of the ferret brain. The Biology and Diseases of the Ferrets. 1998, Williams & Wilkins, Co, Baltimore, 71-102. 2
Google Scholar
Gupta NA, Mells J, Dunham RM, Grakoui A, Handy J, Saxena NK, Anania FA: Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology. 2010, 51: 1584-1592. 10.1002/hep.23569.
Article
PubMed Central
CAS
PubMed
Google Scholar
Venkova K, Palmer JM, Greenwood-Van Meerveld B: Nematode-induced jejunal inflammation in the ferret causes long-term changes in excitatory neuromuscular responses. J Pharmacol Exp Ther. 1999, 290: 96-103.
CAS
PubMed
Google Scholar
Zheng L, Sun Z, Li J, Zhang R, Zhang X, Liu S, Li J, Xu C, Hu D, Sun Y: Pulse pressure and mean arterial pressure in relation to ischemic stroke among patients with uncontrolled hypertension in rural areas of China. Stroke. 2008, 39: 1932-1937. 10.1161/STROKEAHA.107.510677.
Article
PubMed
Google Scholar
Reardon M, Hnatkova K, Malik M: Aging and time-domain and spectral turbulence parameters of signal-averaged electrocardiograms. Pacing Clin Electrophysiol. 1996, 19: 1588-1594. 10.1111/j.1540-8159.1996.tb03185.x.
Article
CAS
PubMed
Google Scholar
Greig NH, Holloway HW, De Ore KA, Jani D, Wang Y, Zhou J, Garant MJ, Egan JM: Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia. 1999, 42: 45-50. 10.1007/s001250051111.
Article
CAS
PubMed
Google Scholar
Tourrel C, Bailbe D, Meile MJ, Kergoat M, Portha B: Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes. 2001, 50: 1562-1570. 10.2337/diabetes.50.7.1562.
Article
CAS
PubMed
Google Scholar
Edwards CM, Stanley SA, Davis R, Brynes AE, Frost GS, Seal LJ, Ghatei MA, Bloom SR: Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab. 2001, 281: E155-E161.
CAS
PubMed
Google Scholar
De Leon DD, Li C, Delson MI, Matschinsky FM, Stanley CA, Stoffers DA: Exendin-(9–39) corrects fasting hypoglycemia in SUR-1−/− mice by lowering cAMP in pancreatic beta-cells and inhibiting insulin secretion. J Biol Chem. 2008, 283: 25786-25793. 10.1074/jbc.M804372200.
Article
PubMed Central
CAS
PubMed
Google Scholar
Flint A, Kapitza C, Zdravkovic M: The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment. Diabetes Obes Metab. 2013, 15: 958-962. 10.1111/dom.12108.
Article
CAS
PubMed
Google Scholar
Shirazi R, Palsdottir V, Collander J, Anesten F, Vogel H, Langlet F, Jaschke A, Schurmann A, Prevot V, Shao R, Jansson JO, Skibicka KP: Glucagon-like peptide 1 receptor induced suppression of food intake, and body weight is mediated by central IL-1 and IL-6. Proc Natl Acad Sci U S A. 2013, 110: 16199-16204. 10.1073/pnas.1306799110.
Article
PubMed Central
CAS
PubMed
Google Scholar
Van Bloemendaal L, Ten Kulve JS, La Fleur SE, Ijzerman RG, Diamant M: Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol. 2013, 221: T1-T16. 10.1530/JOE-13-0414.
Article
Google Scholar
Rotondo A, Amato A, Lentini L, Baldassano S, Mule F: Glucagon-like peptide-1 relaxes gastric antrum through nitric oxide in mice. Peptides. 2011, 32: 60-64. 10.1016/j.peptides.2010.09.028.
Article
CAS
PubMed
Google Scholar
Amato A, Cinci L, Rotondo A, Serio R, Faussone-Pellegrini MS, Vannucchi MG, Mule F: Peripheral motor action of glucagon-like peptide-1 through enteric neuronal receptors. Neurogastroenterol Motil. 2010, 22: 664-e203. 10.1111/j.1365-2982.2010.01476.x.
Article
CAS
PubMed
Google Scholar
Ayachi SE, Borie F, Magous R, Sasaki K, Le Nguyen D, Bali JP, Millat B, Jarrousse C: Contraction induced by glicentin on smooth muscle cells from the human colon is abolished by exendin (9–39). Neurogastroenterol Motil. 2005, 17: 302-309. 10.1111/j.1365-2982.2004.00628.x.
Article
CAS
PubMed
Google Scholar
Wei Y, Mojsov S: Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett. 1995, 358: 219-224. 10.1016/0014-5793(94)01430-9.
Article
CAS
PubMed
Google Scholar
Bullock BP, Heller RS, Habener JF: Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology. 1996, 137: 2968-2978.
CAS
PubMed
Google Scholar
Goke R, Larsen PJ, Mikkelsen JD, Sheikh SP: Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci. 1995, 7: 2294-2300. 10.1111/j.1460-9568.1995.tb00650.x.
Article
CAS
PubMed
Google Scholar
Shughrue PJ, Lane MV, Merchenthaler I: Glucagon-like peptide-1 receptor (GLP1-R) mRNA in the rat hypothalamus. Endocrinology. 1996, 137: 5159-5162.
CAS
PubMed
Google Scholar
Baggio LL, Huang Q, Brown TJ, Drucker DJ: A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes. 2004, 53: 2492-2500. 10.2337/diabetes.53.9.2492.
Article
CAS
PubMed
Google Scholar
Abbott CR, Monteiro M, Small CJ, Sajedi A, Smith KL, Parkinson JR, Ghatei MA, Bloom SR: The inhibitory effects of peripheral administration of peptide YY(3–36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res. 2005, 1044: 127-131. 10.1016/j.brainres.2005.03.011.
Article
CAS
PubMed
Google Scholar
Gutzwiller JP, Goke B, Drewe J, Hildebrand P, Ketterer S, Handschin D, Winterhalder R, Conen D, Beglinger C: Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut. 1999, 44: 81-86. 10.1136/gut.44.1.81.
Article
PubMed Central
CAS
PubMed
Google Scholar
Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Villanueva-Penacarrillo ML, Ulusoy NB: Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol. 1997, 273: G920-G927.
CAS
PubMed
Google Scholar
Bucinskaite V, Tolessa T, Pedersen J, Rydqvist B, Zerihun L, Holst JJ, Hellstrom PM: Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat. Neurogastroenterol Motil. 2009, 21: 978-e978. 10.1111/j.1365-2982.2009.01317.x.
Article
CAS
PubMed
Google Scholar
Holmes GM, Browning KN, Tong M, Qualls-Creekmore E, Travagli RA: Vagally mediated effects of glucagon-like peptide 1: in vitro and in vivo gastric actions. J Physiol. 2009, 587: 4749-4759. 10.1113/jphysiol.2009.175067.
Article
PubMed Central
CAS
PubMed
Google Scholar
Andrews PL, Sanger GJ: Nausea and the quest for the perfect anti-emetic. Eur J Pharmacol. 2014, 722: 108-121. 10.1016/j.ejphar.2013.09.072.
Article
CAS
PubMed
Google Scholar
Lachey JL, D'Alessio DA, Rinaman L, Elmquist JK, Drucker DJ, Seeley RJ: The role of central glucagon-like peptide-1 in mediating the effects of visceral illness: differential effects in rats and mice. Endocrinology. 2005, 146: 458-462. 10.1210/en.2004-0419.
Article
CAS
PubMed
Google Scholar
Kanoski SE, Rupprecht LE, Fortin SM, De Jonghe BC, Hayes MR: The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide. Neuropharmacology. 2012, 62: 1916-1927. 10.1016/j.neuropharm.2011.12.022.
Article
PubMed Central
CAS
PubMed
Google Scholar
Richards CA, Andrews PL: Food refusal: a sign of nausea?. J Pediatr Gastroenterol Nutr. 2004, 38: 227-228. 10.1097/00005176-200402000-00025.
Article
CAS
PubMed
Google Scholar
Kiernan BD, Soykan I, Lin Z, Dale A, McCallum RW: A new nausea model in humans produces mild nausea without electrogastrogram and vasopressin changes. Neurogastroenterol Motil. 1997, 9: 257-263. 10.1046/j.1365-2982.1997.d01-61.x.
Article
CAS
PubMed
Google Scholar
Gianaros PJ, Quigley KS, Muth ER, Levine ME, Vasko RC, Stern RM: Relationship between temporal changes in cardiac parasympathetic activity and motion sickness severity. Psychophysiology. 2003, 40: 39-44. 10.1111/1469-8986.00005.
Article
PubMed Central
PubMed
Google Scholar
LaCount LT, Barbieri R, Park K, Kim J, Brown EN, Kuo B, Napadow V: Static and dynamic autonomic response with increasing nausea perception. Aviat Space Environ Med. 2011, 82: 424-433. 10.3357/ASEM.2932.2011.
Article
PubMed Central
PubMed
Google Scholar
Kim JA, Park YG, Cho KH, Hong MH, Han HC, Choi YS, Yoon D: Heart rate variability and obesity indices: emphasis on the response to noise and standing. J Am Board Fam Pract. 2005, 18: 97-103. 10.3122/jabfm.18.2.97.
Article
PubMed
Google Scholar
Doweck I, Gordon CR, Shlitner A, Spitzer O, Gonen A, Binah O, Melamed Y, Shupak A: Alterations in R-R variability associated with experimental motion sickness. J Auton Nerv Syst. 1997, 67: 31-37. 10.1016/S0165-1838(97)00090-8.
Article
CAS
PubMed
Google Scholar
Morrow GR, Andrews PL, Hickok JT, Stern R: Vagal changes following cancer chemotherapy: implications for the development of nausea. Psychophysiology. 2000, 37: 378-384. 10.1111/1469-8986.3730378.
Article
CAS
PubMed
Google Scholar
Kinzig KP, D'Alessio DA, Seeley RJ: The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness. J Neurosci. 2002, 22: 10470-10476.
CAS
PubMed
Google Scholar
Bhandari P, Bingham S, Andrews PL: The neuropharmacology of loperamide-induced emesis in the ferret: the role of the area postrema, vagus, opiate and 5-HT3 receptors. Neuropharmacology. 1992, 31: 735-742. 10.1016/0028-3908(92)90034-M.
Article
CAS
PubMed
Google Scholar
Billig I, Yates BJ, Rinaman L: Plasma hormone levels and central c-Fos expression in ferrets after systemic administration of cholecystokinin. Am J Physiol Regul Integr Comp Physiol. 2001, 281: R1243-R1255.
CAS
PubMed
Google Scholar